Clinical Trials at Yale University School of Medicine
As of August 2026, 66 paid clinical trials are recruiting at Yale University School of Medicine, located at 333 CEDAR ST, LMP 1080, NEW HAVEN, CT 06510-3206, phone (203) 785-4138 in New Haven, Connecticut. Active studies at this site cover conditions such as Advanced Solid Tumor, Breast Cancer and Alcohol Use Disorder. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
66 clinical trials at Yale University School of Medicine
·Clear filters·A Study of Brenipatide in Adult Participants With Schizophrenia
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Pompe Disease Registry Protocol
Fabry Disease Registry & Pregnancy Sub-registry
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Registry for Stage 2 Type 1 Diabetes
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Common conditions studied in New Haven
- Advanced Solid Tumor (22 active studies)
- Breast Cancer (20 active studies)
- Alcohol Use Disorder (16 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Advanced Solid Tumors (12 active studies)
- Heart Failure (11 active studies)
Leading research sponsors in New Haven
- Yale University
- National Cancer Institute (NCI)
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- SWOG Cancer Research Network
Frequently asked questions
How many paid clinical trials are currently recruiting in New Haven?
There are approximately 848 recruiting clinical trials in New Haven, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Haven pay participants?
Most recruiting trials in New Haven compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Haven?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Haven?
The most common conditions under active study in New Haven include Advanced Solid Tumor (22), Breast Cancer (20), Alcohol Use Disorder (16), Acute Myeloid Leukemia (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Haven?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Haven on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Haven?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Haven?
Recruiting research sites in New Haven include Yale University, Yale Cancer Center, Yale New Haven Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Haven right now?
The largest active categories in New Haven are Cancer & tumors (312), Neurology & pain (46), Cardiovascular (39). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Yale University School of Medicine?
Yale University School of Medicine is located at 333 CEDAR ST, LMP 1080, NEW HAVEN, CT 06510-3206. Use the Google Maps link in the intro above to get directions.
How do I contact Yale University School of Medicine?
You can reach Yale University School of Medicine by phone at (203) 785-4138. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.